Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention
Jyong Biotech (NASDAQ:MENS), a Taiwan-based biotechnology company, marked two significant milestones: its Nasdaq IPO bell ringing ceremony on July 2, 2025, and participation in the BIO 2025 International Convention from June 16-19 in Boston.
The company showcased its flagship product MCS®-2, targeting the benign prostatic hyperplasia (BPH) market, which is projected to grow from $4.1 billion in 2020 to $9.8 billion by 2026. Jyong Biotech specializes in plant-derived drugs for urinary system diseases, focusing on the U.S., EU, and Asian markets.
The company plans to expand MCS®-2's market penetration through regional licensing partnerships while pursuing research and development in the urology sector.
Jyong Biotech (NASDAQ:MENS), un'azienda biotecnologica con sede a Taiwan, ha raggiunto due importanti traguardi: la cerimonia del suono della campana per l'IPO al Nasdaq il 2 luglio 2025 e la partecipazione al BIO 2025 International Convention dal 16 al 19 giugno a Boston.
L'azienda ha presentato il suo prodotto di punta MCS®-2, rivolto al mercato dell'iperplasia prostatica benigna (BPH), previsto in crescita da 4,1 miliardi di dollari nel 2020 a 9,8 miliardi entro il 2026. Jyong Biotech è specializzata in farmaci di origine vegetale per le malattie del sistema urinario, con un focus sui mercati di Stati Uniti, Unione Europea e Asia.
L'azienda intende ampliare la penetrazione di mercato di MCS®-2 attraverso partnership di licenza regionali, continuando al contempo la ricerca e lo sviluppo nel settore urologico.
Jyong Biotech (NASDAQ:MENS), una empresa biotecnológica con sede en Taiwán, celebró dos hitos importantes: la ceremonia de toque de campana en su IPO en Nasdaq el 2 de julio de 2025 y su participación en la Convención Internacional BIO 2025 del 16 al 19 de junio en Boston.
La compañía presentó su producto estrella MCS®-2, dirigido al mercado de la hiperplasia prostática benigna (HPB), que se proyecta crecer de
La empresa planea ampliar la penetración de mercado de MCS®-2 mediante asociaciones de licencias regionales, mientras continúa con la investigación y desarrollo en el sector de urología.
Jyong Biotech (NASDAQ:MENS)는 대만에 본사를 둔 바이오테크 기업으로, 2025년 7월 2일 나스닥 IPO 종 타종식과 6월 16일부터 19일까지 보스턴에서 열린 BIO 2025 국제 컨벤션에 참가하는 두 가지 중요한 이정표를 세웠습니다.
회사는 양성 전립선 비대증(BPH) 시장을 겨냥한 주력 제품 MCS®-2를 선보였으며, 해당 시장은 2020년 41억 달러에서 2026년까지 98억 달러로 성장할 것으로 예상됩니다. Jyong Biotech는 요로계 질환을 위한 식물 유래 의약품을 전문으로 하며, 미국, 유럽연합, 아시아 시장에 중점을 두고 있습니다.
회사는 지역별 라이선스 파트너십을 통해 MCS®-2의 시장 침투를 확대하고, 비뇨기과 분야의 연구개발을 지속할 계획입니다.
Jyong Biotech (NASDAQ:MENS), une entreprise biotechnologique basée à Taïwan, a franchi deux étapes importantes : la cérémonie de sonnerie de la cloche pour son introduction en bourse au Nasdaq le 2 juillet 2025, et sa participation à la Convention Internationale BIO 2025 du 16 au 19 juin à Boston.
L'entreprise a présenté son produit phare MCS®-2, destiné au marché de l'hyperplasie bénigne de la prostate (HBP), dont la valeur devrait passer de 4,1 milliards de dollars en 2020 à 9,8 milliards d'ici 2026. Jyong Biotech est spécialisée dans les médicaments d'origine végétale pour les maladies du système urinaire, avec un focus sur les marchés américain, européen et asiatique.
L'entreprise prévoit d'élargir la pénétration du marché de MCS®-2 via des partenariats de licence régionaux tout en poursuivant la recherche et le développement dans le secteur de l'urologie.
Jyong Biotech (NASDAQ:MENS), ein biotechnologisches Unternehmen mit Sitz in Taiwan, erreichte zwei bedeutende Meilensteine: die Eröffnungszeremonie zur Nasdaq-IPO am 2. Juli 2025 und die Teilnahme an der BIO 2025 International Convention vom 16. bis 19. Juni in Boston.
Das Unternehmen präsentierte sein Hauptprodukt MCS®-2, das den Markt für benigne Prostatahyperplasie (BPH) adressiert, der voraussichtlich von 4,1 Milliarden US-Dollar im Jahr 2020 auf 9,8 Milliarden US-Dollar bis 2026 wachsen wird. Jyong Biotech ist auf pflanzenbasierte Medikamente für Erkrankungen des Harnsystems spezialisiert und konzentriert sich auf die Märkte in den USA, der EU und Asien.
Das Unternehmen plant, die Marktdurchdringung von MCS®-2 durch regionale Lizenzpartnerschaften auszubauen und gleichzeitig Forschung und Entwicklung im Bereich Urologie voranzutreiben.
- None.
- None.
Insights
Jyong Biotech's Nasdaq IPO and BIO 2025 presence positions them to target the growing $9.8B BPH market with plant-based alternatives.
Jyong Biotech's recent Nasdaq IPO represents a significant milestone for this Taiwan-based biotechnology company specializing in plant-derived treatments for urinary system diseases. The IPO provides crucial access to global capital markets that will be necessary to fund their commercial expansion and R&D pipeline.
The company's flagship product MCS®-2 targets the benign prostatic hyperplasia (BPH) market, which is projected to grow substantially from
The company is implementing a dual-track strategic approach: prioritizing global licensing and sales network expansion for MCS®-2 while simultaneously developing additional plant-based treatments in urology. Their differentiation lies in offering plant-derived alternatives in a market traditionally dominated by synthetic pharmaceuticals, potentially addressing safety concerns.
While the press release highlights their strategic positioning and market opportunity, it notably lacks specific details about MCS®-2's regulatory status, clinical trial results, or timeline to commercialization. These factors will be critical determinants of the company's near-term prospects following their public debut. As with many newly public biotech companies, execution of their commercialization strategy and the strength of their intellectual property will be key success factors to monitor.
New Taipei City, Taiwan, July 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced completion of its Nasdaq IPO ceremony, and that it participated at the world's largest biotechnology exhibition BIO 2025 International Convention, where it engaged with other global pharmaceutical companies.
During the BIO 2025 exhibition in Boston, USA, from June 16 to 19, 2025, Jyong Biotech shared and exchanged views about its flagship product, MCS®-2, with other pharmaceutical players from the U.S., EU, Canada, Mexico, Japan, South Korea, China, and the Middle East. The drug targets the benign prostatic hyperplasia (BPH) market, driven by global aging and escalating obesity rates, with market size projections soaring from
The Company’s Chairwoman, Fu-Feng Kuo, rang the Company's NASDAQ listing bell on July 2 at the Nasdaq Stock Exchange, signifying a pivotal moment for Jyong Biotech in accessing the global capital market. Jyong Biotech believes that this strategic listing positions the Company to leverage its safety differentiators in plant-based new drugs to capture opportunities in the BPH, lower urinary tract symptoms (LUTS), and prostate cancer prevention sectors, traditionally dominated by synthetic drugs.
The Company aims to maximize MCS®-2 market penetration in key regions such as the U.S., Europe, and Asia through regional licensing partnerships while simultaneously exploring opportunities in emerging markets. Leveraging the Nasdaq platform, Jyong Biotech is executing a dual-track approach, prioritizing global licensing and sales network expansion for MCS®-2 alongside research and development in the urology sector to establish a comprehensive matrix of plant-based new drug offerings.
The Company’s Chairwoman, Fu-Feng Kuo, commented: "We believe that from the international resonance of BIO 2025 to the completion of our IPO and the listing of our shares on Nasdaq, Jyong Biotech is poised for global prominence. Anchored in clinical evidence, we are committed to meeting the urgent demand for safe medications in an aging society, setting a new standard for plant-based new drug innovation on a global scale."
About Jyong Biotech Ltd.
Headquartered in Taiwan, Jyong Biotech Ltd.is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, MCS®-2, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.
For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Investor Relations
WFS Investor Relations Inc.
Janice Wang
Email: services@wealthfsllc.com
Phone:+1 628 283 9214
FAQ
When did Jyong Biotech (MENS) ring the Nasdaq bell?
What is the market size projection for BPH treatment that Jyong Biotech's MCS®-2 targets?
What is Jyong Biotech's (MENS) main product and target market?
Where and when did Jyong Biotech participate in the BIO 2025 Convention?
What is Jyong Biotech's (MENS) business expansion strategy?
